Abstract
Allergic contact dermatitis (ACD) to cosmetics is extremely common—probably the most common reason patients present for patch testing. The diagnosis should initially be suspected based on the patient history and the distribution of the dermatitis. Once the diagnosis is suspected, empiric recommendations for low allergenicity products should be implemented until patch testing is performed. The face is exposed to greatest number of cosmetics, and as a result, facial dermatitis is the prototypical presentation of cosmetic contact dermatitis. In particular, the eyelids are frequently involved, with common sources including shampoo, conditioner, facial cleansers, makeup remover, mascara, nail polish, acrylic nails, makeup sponges, eyelash curlers, and allergens transferred from the hands. Other typical facial distributions include lateral facial dermatitis, central facial dermatitis, and generalized facial dermatitis, each with its own unique set of most likely causes. Lateral facial and/or neck dermatitis is often a “rinse-off” pattern, with shampoo and/or conditioner rinsing down over these areas. Central facial dermatitis, when due to ACD, can be due to gold being released from gold rings and contaminating makeup foundation or to ingredients in moisturizers, wrinkle creams, topical medications, or makeup. Sparing of the lateral face is largely due to the fact that patients are more assiduous about applying the aforementioned substances to the central face than to the lateral face. Generalized facial dermatitis should trigger consideration of airborne contactants, facial cleansers, makeup foundation, and moisturizers and medications that are being applied confluently. Once adequate patch testing has been performed, there are a number of extremely helpful resources to help patients find products that are safe for use, such as the American Contact Dermatitis Society’s “Contact Allergen Management Program” app.
Similar content being viewed by others
References
Amin KA, Belsito DV (2006) The aetiology of eyelid dermatitis: a 10-year retrospective analysis. Contact Dermatitis 55(5):280–285
Pascher F (1982) Adverse reactions to eye area cosmetics and their management. J Soc Cosmet Chem 33:249
Mohajerin AH (1972) Common cutaneous disorders of the eyelids. Cutis 10:279
Rietschel RL, Warshaw EM, Sasseville D, Fowler JF, DeLeo V, Belsito DV, Taylor JS, Storrs FJ, Mathias CG, Maibach HI, Marks JG, Zug KA, Pratt M, North American Contact Dermatitis Group (2007) Common contact allergens associated with eyelid dermatitis: data from the North American Contact Dermatitis Group 2003-2004 study period. Dermatitis 18(2):78–81
Dejobert Y, Delaporte E, Piette F, Thomas P (2005) Eyelid dermatitis with positive patch test to coconut diethanolamide. Contact Dermatitis 52(3):173
Gallo R, Marro I, Pavesi A (2005) Allergic contact dermatitis from shellac in mascara. Contact Dermatitis 53(4):238
Le Coz CJ et al (2002) Allergic contact dermatitis from shellac in mascara. Contact Dermatitis 46(3):149–152
Saxena M, Warshaw E, Ahmed DD (2001) Eyelid allergic contact dermatitis to black iron oxide. Am J Contact Dermat 12(1):38–39
Fisher AA (1977) Allergen replacements in allergic dermatitis. Int J Dermatol 16(5):319–328
Guin JD (2000) Eyelid dermatitis from benzophenone used in nail enhancement. Contact Dermatitis 43(5):308–309
Moffitt DL, Sansom JE (2002) Allergic contact dermatitis from phthalic anhydride/trimellitic anhydride/glycols copolymer in nail varnish. Contact Dermatitis 46(4):236
Frosch PJ, Kligman AM (1977) A method for appraising the stinging capacity of topically applied substances. J Soc Cosmet Chem 28:197
Lahti A (1978) Skin reactions to some antimicrobial agents. Contact Dermatitis 4(5):302–303
Lahti A, Oikarinen A, Viinikka L, Ylikorkala O, Hannuksela M (1983) Prostaglandins in contact urticaria induced by benzoic acid. Acta Derm Venereol 63(5):425–427
Lahti A, Väänänen A, Kokkonen EL, Hannuksela M (1987) Acetylsalicylic acid inhibits non-immunologic contact urticaria. Contact Dermatitis 16(3):133–135
Maibach HI, Engasser P (1988) Management of cosmetic intolerance syndrome. Clin Dermatol 6(3):102–107
Sugai T, Takahashi Y, Takagi T (1977) Pigmented cosmetic dermatitis and coal tar dyes. Contact Dermatitis 3(5):249–256
Nakavama H, Hanaoka H, Ohshiro A (1974) Allergen controlled system (ACS). Kanehara Shuppan Co, Tokyo
Jacob SE, Castanedo-Tardan MP (2008) A diagnostic pearl in allergic contact dermatitis to fragrances: the atomizer sign. Cutis 82(5):317–318
Britz MB, Maibach HI (1979) Human cutaneous vulvar reactivity to irritants. Contact Dermatitis 5(6):375–377
Lewis FM, Harrington CI, Gawkrodger DJ (1994) Contact sensitivity in pruritus vulvae: a common and manageable problem. Contact Dermatitis 31(4):264–265
Lewis FM, Shah M, Gawkrodger DJ (1997) Contact sensitivity in pruritus vulvae: patch test results and clinical outcome. Am J Contact Dermat 8(3):137–140
Petersen CS (1997) Lack of contact allergy in consecutive women with vulvodynia. Contact Dermatitis 37(1):46–47
Nunns D, Ferguson J, Beck M, Mandal D (1997) Is patch testing necessary in vulval vestibulitis? Contact Dermatitis 37(2):87–89
Fisher AA (1973) Allergic reaction to feminine hygiene sprays. Arch Dermatol 108(6):801–802
Gowdy JM (1972) Feminine deodorant sprays. N Engl J Med 287(4):203
Paley K, English JC 3rd, Zirwas MJ (2008) Pterygium inversum unguis secondary to acrylate allergy. J Am Acad Dermatol 58(2 Suppl):S53–S54
Ramos L, Cabral R, Goncalo M (2014) Allergic contact dermatitis caused by acrylates and methacrylates—a 7-year study. Contact Dermatitis 71(2):102–107
Drucker AM, Pratt MD (2011) Acrylate contact allergy: patient characteristics and evaluation of screening allergens. Dermatitis 22(2):98–101
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The author has served as a consultant for numerous personal care product and pharmaceutical companies which are listed in the following table.
Ethical Approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Matthew J Zirwas commercial relationships, updated Jan 2018.
Company | Product | Condition | Role | Recipient |
---|---|---|---|---|
Regeneron/Sanofi | Dupixent | Atopic dermatitis | Speaker, consultant, investigator | Self |
Fit Bit | Fitbit | Fitness/activity tracker | Consultant | Self |
Genench/Novartis | Xolair | Chronic urticaria | Speaker | Self |
L’Oreal | CeraVe | Xerosis, dermatitis | Consultant | Self |
Menlo | Serlopitant | Pruritus | Consultant | Self |
AsepticMD | AsepticMD | Acne, keratosis pilaris | Part owner | Self |
Leo | Tralokinumab | Atopic Dermatitis | Investigator | Employer |
Janssen | Guselkumab | Psoriasis | Investigator | Employer |
Incyte | Baricitinib | Atopic Dermatitis | Investigator | Employer |
Foamix | Minocycline | Rosacea, Acne | Investigator | Employer |
DS Biopharma | DS107 | Atopic Dermatitis | Investigator | Employer |
UCB | Bimekizumab | Psoriasis | Investigator | Employer |
Rights and permissions
About this article
Cite this article
Zirwas, M.J. Contact Dermatitis to Cosmetics. Clinic Rev Allerg Immunol 56, 119–128 (2019). https://doi.org/10.1007/s12016-018-8717-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-018-8717-9